8-K: OS Therapies Announces Third Quarter 2024 Financial Results and Provides Business Update

OS Therapies reports its third quarter 2024 financial results, highlighting the completion of its Phase 2b clinical trial for OST-HER2 and anticipating topline data in December 2024.

Summary

• OS Therapies, a clinical-stage biotechnology company, has released its financial results for the third quarter of 2024.
• The company completed its initial public offering and finished dosing the final patient in its Phase 2b clinical trial of OST-HER2 for osteosarcoma.
• Topline data from the Phase 2b trial is expected to be released in December 2024.
• The company is in discussions with the FDA regarding Breakthrough Therapy Designation for OST-HER2.
• OS Therapies recorded a net operating loss of $2.875 million in Q3 2024, compared to a $2.006 million loss in Q3 2023.
• The increased loss was primarily due to expenses associated with the initial public offering.
• Net loss per share was $0.18 on 15.897 million weighted average shares outstanding in Q3 2024, compared to a loss of $0.38 per share on 5.340 million shares in Q3 2023.
• The company anticipates generating revenue through the sale of a priority review voucher and licensing rights to its products.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the completion of the Phase 2b trial and the anticipation of topline data, as well as the multiple regulatory designations. However, the company is still pre-revenue and has reported increased losses, which tempers the overall sentiment.

Positives

• The company has completed the treatment phase of its Phase 2b clinical trial for OST-HER2.
• OST-HER2 has received multiple designations from regulatory agencies, including Rare Pediatric Disease Designation.
• The company is in active discussions with the FDA regarding Breakthrough Therapy Designation.
• The company anticipates generating revenue through the sale of a priority review voucher and licensing rights.
• The company has completed its initial public offering.

Negatives

• The company recorded a net operating loss of $2.875 million in the third quarter of 2024, an increase from $2.006 million in the same period last year.
• The increased loss was largely due to expenses associated with the initial public offering.
• The company is currently pre-revenue.

Risks

• The company's future success is dependent on the outcome of clinical trials and regulatory approvals.
• The company is currently pre-revenue and relies on future milestones to generate income.
• The company's financial performance is subject to risks and uncertainties, including those described in the prospectus filed with the SEC.

Future Outlook

The company anticipates generating revenue through the sale of a priority review voucher and licensing rights to its products. Topline data from the Phase 2b trial is expected in December 2024, and the company is in discussions with the FDA regarding Breakthrough Therapy Designation for OST-HER2.

Management Comments

• Paul Romness, MHP, Chairman & CEO of OS Therapies, stated that the third quarter was pivotal for the company, with the completion of the IPO and the final patient dosing in the Phase 2b trial.
• He also mentioned that the company is looking forward to releasing topline data in December and engaging with the FDA to get the cancer immunotherapy to patients quickly.

Industry Context

This announcement is relevant to the biotechnology and pharmaceutical industries, particularly in the area of cancer immunotherapy and antibody drug conjugates. The company's focus on osteosarcoma, a rare cancer, aligns with the growing interest in developing treatments for orphan diseases. The company's progress with OST-HER2 and its discussions with the FDA are important milestones in the development of new cancer therapies.

Comparison to Industry Standards

• OS Therapies is a clinical-stage company, so direct revenue comparisons to established pharmaceutical companies are not applicable.
• The company's focus on a rare disease like osteosarcoma is similar to other biotech companies targeting niche markets, such as companies like BioMarin Pharmaceutical or Ultragenyx Pharmaceutical.
• The completion of a Phase 2b trial and the anticipation of topline data are typical milestones for companies in this stage of development, similar to companies like Arcus Biosciences or Iovance Biotherapeutics.
• The company's net loss is expected for a pre-revenue biotech company, and the increase in loss due to IPO expenses is also typical.
• The company's pursuit of regulatory designations like Rare Pediatric Disease Designation and Breakthrough Therapy Designation is a common strategy to expedite the approval process, similar to companies like Sarepta Therapeutics.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the clinical trials.
• Patients with osteosarcoma may benefit from the potential approval of OST-HER2.
• Employees are impacted by the company's progress and financial performance.
• The company's suppliers and partners are impacted by the company's progress and financial performance.

Next Steps

• The company will release topline data from the Phase 2b clinical trial of OST-HER2 in December 2024.
• The company will engage with the FDA regarding potential approval pathways for OST-HER2.
• The company will continue to advance its Antibody Drug Conjugate (ADC) platform.

Key Dates

Keywords

OST-HER2, Osteosarcoma, Immunotherapy, Clinical Trial, Biotechnology, FDA, Rare Pediatric Disease Designation, Antibody Drug Conjugate, Phase 2b, Priority Review Voucher